Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Solid Tumor, Adult 1Solid Tumor 1Sezary Syndrome 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pain 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rosuvastatin Calcium 5capivasertib 2Digoxin 2sotorasib 1ibrutinib 1Midazolam 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Healthy Participants × Dextromethorphan × Clear all
NCT07241065 2026-04-15

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

AstraZeneca

Phase 1 Recruiting
42 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡